NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial Readiness

[ad_1] Clinical efficacy top-line results of PARADIGM, a Phase 2b trial in ALS, expected in December 2023 CAMBRIDGE, Mass., Nov. 13, 2023 /PRNewswire/ — NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a…

Dongfeng Motor Group Launches Brand of AI-Powered Cars

[ad_1] Dongfeng Motor Group has launched a brand of so-called smartcars, joining many companies in developing vehicles using artificial intelligence. The Chinese carmaker said in an exchange filing that the…

WSJ News Exclusive | Key Witness at Sam Bankman-Fried Trial to Launch New Crypto Exchange

[ad_1] A group of former FTX executives, including one who served as a key witness against Sam Bankman-Fried, are teaming up to build a new cryptocurrency exchange that aims to…

WSJ News Exclusive | Delays in Acela Upgrade Have Cost Amtrak $140 Million…and Counting

[ad_1] Listen to article (2 minutes) The three-year wait for Amtrak’s overdue new Acela train fleet has cost the railroad $140 million and counting, documents show, a setback for a…

Why Rivian Can’t Be the Next Tesla

[ad_1] Rivian is on a better road than Lucid, but none of America’s electric-vehicle startups looks much like being the next Tesla. Rivian is finding its cruising speed—slower but more…

Elon Musk Says His New AI Bot ‘Grok’ Will Have Sarcasm and Access to X Information

[ad_1] Updated Nov. 4, 2023 1:10 pm ET Elon Musk gave a glimpse of his artificial-intelligence startup’s first product: a bot named Grok whose sense of humor he demonstrated with…

Tech Giants Spend Billions on AI Startups—And Get Just as Much Back

[ad_1] Updated Nov. 3, 2023 1:41 pm ET Amazon, Google and Microsoft have spent the past year investing billions of dollars in artificial-intelligence startups—while also charging those fledgling companies a…

Obesity Drug Demand Outstrips Supply

[ad_1] Eli Lilly’s blockbuster diabetes medication Mounjaro is expected to receive Food and Drug Administration approval as an obesity treatment before the end of the year, which would lead to…

QIAGEN and Element Biosciences partner to offer complete next-generation sequencing workflows for the AVITI System

[ad_1] Partnership combines QIAGEN’s QIAseq panels, CLC LightSpeed, and QCI Interpret software to support Element’s AVITI System users in genomic analysis Element and QIAGEN are advancing genomic applications with innovative technology…

Synechron Announces Key Promotions and New Organizational Structure to Streamline Operations and Enable Next Phase of Growth

[ad_1] NEW YORK, LONDON and PUNE, India, Nov. 2, 2023 /PRNewswire/ — Synechron, Inc., a leading global digital transformation consulting firm focused on financial services and technology organizations, announces key leadership…